subscribeSubscribe
price-trendAsk Us
Fostrox + Lenvima® holds promise of greatly improved outcomes

Fostrox + Lenvima® holds promise of greatly improved outcomes
PR NEWSWIRE
27 Jun 2024
Share Share
Medivir Selects CRO For Phase 2b HCC Study With Fostrox + Lenvima

Medivir Selects CRO For Phase 2b HCC Study With Fostrox + Lenvima
PR NEWSWIRE
19 Jun 2024
Share Share
Medivir to Present Fostrox + Lenvima Data in HCC at ESMO GI

Medivir to Present Fostrox + Lenvima Data in HCC at ESMO GI
PR NEWSWIRE
29 Apr 2024
Share Share
Medivir presents data on additive activity of fostrox with Lenvima or sorafenib

Medivir presents data on additive activity of fostrox with Lenvima or sorafenib
PR NEWSWIRE
07 Sep 2023
Share Share
Medivir reports promising interim data

Medivir reports promising interim data
PR NEWSWIRE
04 Sep 2023
Share Share
Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included
PR NEWSWIRE
14 Aug 2023
Share Share
China approves Medivir’s patent application for Fostrox

China approves Medivir’s patent application for Fostrox
PHARMACEUTICAL TECHNOLOGY
19 Jun 2023
Share Share
Medivir to present data on efficacy of fostrox in combination with anti-PD1

Medivir to present data on efficacy of fostrox in combination with anti-PD1
PR NEWSWIRE
17 Mar 2023
Share Share
First patient dosed in Ph 2a part of Medivir`s study with fostrox with Lenvima

First patient dosed in Ph 2a part of Medivir`s study with fostrox with Lenvima
PR NEWSWIRE
14 Mar 2023
Share Share